优化型CXCR4靶向诊疗配对药物的开发
研究基于LY2510924构效关系设计新型环肽BL34,用68Ga和177Lu标记后,在套细胞淋巴瘤Z138小鼠模型中评估PET/SPECT显像、生物分布及177Lu治疗疗效。结果显示BL34的CXCR4结合力较LY2510924提高3倍,68Ga-BL34显像对比度高,177Lu-BL34治疗呈剂量依赖性生存获益,但治疗组出现转移性复发。
要点
- 优化的环肽BL34对CXCR4的结合力较LY2510924提高3倍。
- 68Ga-BL34注射后1小时肿瘤摄取15.1±3.1 %ID/g,主要经肾脏排泄。
- 177Lu-BL34治疗呈剂量依赖性生存获益,但治疗组出现转移性复发。
核心结论
- BL34是一种新的CXCR4靶向药效团,68Ga-BL34和177Lu-BL34在临床前研究中显示出优异的显像和治疗特性,是有前景的临床转化候选药物。
研究设计与样本
- 基于LY2510924构效关系设计并固相合成候选抑制剂,用细胞实验评估CXCR4结合,将优化环肽经Lys-半胱磺酸连接子和DOTA螯合剂修饰制成BL34。
- 另合成含鸟氨酸或二氨基庚二酸连接子的类似物并评估,所有放射性示踪剂在套细胞淋巴瘤Z138小鼠模型中行PET/SPECT显像和生物分布研究。
- 177Lu-BL34治疗疗效在Z138荷瘤小鼠中评估,设30 MBq组、60 MBq组和对照组。
主要发现
- 优化环肽的CXCR4结合力较LY2510924提高3倍。
- 68Ga-BL34注射后1和2小时肿瘤显像对比度高,生物分布证实注射后1小时肿瘤摄取15.1±3.1 %ID/g,主要经肾脏排泄,肾摄取2.4±0.4 %ID/g。
- 177Lu-BL34的SPECT显像结果相似,非靶器官快速经肾排泄,注射后72小时肿瘤仍有较高摄取,各时间点肿瘤摄取高而所有非靶器官摄取低。
- 用LY2510924阻断研究进一步证实了特异性。
- 治疗研究显示177Lu-BL34呈剂量依赖性生存获益,治疗组出现转移性复发;改变连接子附着位点侧链长度不影响生物分布或肿瘤摄取。
临床怎么用
- BL34作为CXCR4靶向放射性诊疗配对药物,临床前显示高肿瘤对比度和剂量依赖性治疗获益,支持进一步临床转化评估。
- 治疗组出现转移性复发,提示后续临床研究需关注疗效深度与复发监测。
局限性
- 研究为临床前小鼠模型数据,尚未在人体中验证。
- 治疗研究观察到治疗组出现转移性复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We developed a new C-X-C chemokine receptor 4 (CXCR4)-targeting radiolabeled peptide, [68Ga]Ga/[177Lu]Lu-BL34, using a novel and potent cyclic peptide based on structure-activity relationship studies of LY2510924. Methods: Candidate inhibitors were designed on the basis of structure-activity studies and synthesized using solid-phase techniques, and their CXCR4 binding was assessed using a cell-based assay. An optimized cyclic peptide sequence was modified with a Lys-cysteic acid linker and DOTA chelator to make BL34. Other analogs possessing ornithine or diaminopimelic acid linkers were also synthesized and assessed. All radiotracers were assessed in mice engrafted with a mantle cell lymphoma model (Z138) via PET/SPECT imaging and biodistribution studies. Therapeutic efficacy of [177Lu]Lu-BL34 was assessed in Z138-engrafted mice with groups of 30 and 60 MBq and a control. Results: The optimized cyclic peptide showed a 3-fold improvement in CXCR4 binding compared with that of LY2510924. [68Ga]Ga-BL34 showed high imaging contrast for the tumor at 1 and 2 h after injection. Biodistribution studies confirmed these results, with an uptake of 15.1 ± 3.1 %ID/g in the tumor at 1 h after injection and primarily renal excretion with a kidney uptake of 2.4 ± 0.4 %ID/g. SPECT imaging of [177Lu]Lu-BL34 showed similar results, with rapid renal excretion of [177Lu]Lu-BL34 from nontarget organs and relatively high uptake in tumors up to 72 h after injection. Biodistribution studies confirmed high tumor uptake at all time points, with low uptake across all nontarget organs. Blocking studies with LY2510924 further confirmed specificity. Therapy studies showed dose-dependent survival benefit with [177Lu]Lu-BL34 treatment, with metastatic recurrence in the treatment groups. Changing the side chain length at the linker attachment site did not affect the biodistribution or tumor uptake. Conclusion: We report a new CXCR4-targeting pharmacophore that can be used as a radiotheranostic. [68Ga]Ga-BL34 and [177Lu]Lu-BL34 showed excellent imaging and therapeutic properties in preclinical studies and are promising candidates for clinical translation.
引用
- Kwon D, Bloise I, Zhang Z, et al. Development of an Optimized CXCR4-Targeting Theranostic Pair. J Nucl Med. 2026. PMID: 41611474. doi:10.2967/jnumed.125.269933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。